Compare Ginkgo Bioworks Holdings Inc (DNA) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Firy Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Firy Inc. trades at $12.03 (market cap $199.80M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3.8× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Firy Inc. for 13 Days on average.
| DNA | FIRY | |
|---|---|---|
Market Cap | $763.64M | $199.80M |
Volume | 3,204,177 | 92,993 |
Sector | Health | Technology |
52-Week High | $15.83 | $13.10 |
52-Week Low | $5.48 | $2.28 |
Typical Hold Time | 7 Days | 13 Days |
Enterprise Value | $865.59M | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
FIRY trades at $12.07, up 1.86% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but a net loss, continuing a trend of negative profitability. Recent developments include a major legal victory with a $719 million judgment and the appointment of Marc Lasry to the board, signaling strategic shifts under its new holding company structure.
The outlook remains challenged by persistent cash burn and negative margins, though the legal win offers potential upside. Risks include high cash outflow and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, reflecting uncertainty around the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
